Evidence map›Paper›PMID 40499013›Full record

ArticleBlood2025

Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women.

Yash Pershad, Md Mesbah Uddin, Liying Xue, Jeffrey Haessler, Jason M Collins, Taralynn M Mack, Elena Glick, Veronica Glaser, Kun Zhao, Siddhartha Jaiswal and 10 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Clonal Signatures of Telomere Biology Disorders.Current hematologic malignancy reports · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.Journal of the American College of Cardiology · 2025
    Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Yash PershadDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2282-1403
Md Mesbah UddinCardiovascular Research Center and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0003-1846-0411
Liying XueCardiovascular Research Center and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Jeffrey HaesslerDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.
Jason M CollinsDepartment of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-2903-797X
Taralynn M MackDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-1043-2950
Elena GlickDepartment of Human Genetics, University of Michigan, Ann Arbor, MI.
Veronica GlaserDepartment of Human Genetics, University of Michigan, Ann Arbor, MI.
Kun ZhaoDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Siddhartha JaiswalDepartment of Pathology, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-9597-0477
JoAnn E MansonDepartment of Medicine, Mass General Brigham, Harvard Medical School, Boston, MA.
Urvashi PandeyDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.
Pinkal DesaiDivision of Hematology and Medical Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY.
Pradeep NatarajanCardiovascular Research Center and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Michael C HonigbergCardiovascular Research Center and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-8630-5021
Charles KooperbergDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.
Eric A WhitselDepartment of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0003-4843-3641
Jacob O KitzmanDepartment of Human Genetics, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-6145-882X
Alexander G BickDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Alexander P ReinerDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.

Funding

WOMEN'S HEALTH INITIATIVE - CLINICAL COORDINATING CENTER: TASK AREA B - LONG LIFE STUDY VISIT 2 LIMITED HOME VISIT75N92021D00001 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L. · 2021 to 2025
$52.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00002 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WACTAWSKI-WENDE, JEAN · 2021 to 2025
$6.9M
Clonal Hematopoiesis Aging Resiliency MechanismsR01AG088657 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Alexander Bick, Siddhartha Jaiswal · 2024 to 2026
$6.6M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00004 · NHLBI · STANFORD UNIVERSITY · PI STEFANICK, MARCIA · 2021 to 2025
$6.5M
Clonal hematopoiesis in the Womens Health Initiative Memory StudyR01HL148565 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ALEXANDER P REINER, Eric A. Whitsel · 2019 to 2026
$5.9M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00003 · NHLBI · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA · 2021 to 2025
$5.0M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI VITOLINS, MARA · 2021 to 2025
$4.2M
Targeting Clonal Hematopoiesis of Indeterminate Potential Using Human GeneticsDP5OD029586 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BICK, ALEXANDER · 2020 to 2024
$2.3M
NHLBI NIH HHS 75N92021D00001NHLBI NIH HHS 75N92021D00002NHLBI NIH HHS R01 HL148565NIA NIH HHS R01 AG088657NIGMS NIH HHS T32 GM007347NIH HHS DP5 OD029586Wellcome TrustWHI NIH HHS 75N92021D00003WHI NIH HHS 75N92021D00004WHI NIH HHS 75N92021D00005
6 · The paper itself

Abstract

abstractClonal hematopoiesis of indeterminate potential (CHIP) is associated with increased mortality and malignancy risk, yet the determinants of clonal expansion remain poorly understood. We performed sequencing at a depth of coverage of >4000× for CHIP mutations in 6976 postmenopausal women from the Women's Health Initiative (WHI) at 2 time points: the WHI baseline examination and ∼16 years later at the Long Life Study (LLS) visit. Among 3685 CH mutations detected at baseline (variant allele fraction [VAF] of ≥0.5%), 24% were not detected at LLS, 26% were micro-CH at LLS (0.5% ≤ VAF < 2%), and 50% were CHIP (VAF ≥ 2%). We confirmed that clonal expansion is highly dependent on initial clone size and CHIP driver gene, with SF3B1 and JAK2 mutations exhibiting the fastest growth rate. We identified germ line variants in TERT, IL6R, TCL1A, and MSI2 that modulate clonal expansion rate. Measured baseline leukocyte telomere length showed differential effects on incident CHIP risk, with shorter baseline leukocyte telomere length predisposing to incident PPM1D mutations and longer baseline leukocyte telomere length favoring incident DNMT3A mutations. We discovered that the IL6R missense variant p.Asp358Ala specifically impairs TET2 clonal expansion, supported by direct measurements of soluble interleukin-6 receptor and interleukin-6. Faster clonal growth rate was associated with increased risk of cytopenia, leukemia, and all-cause mortality. Notably, CHIP clonal expansion rate mediated 34.4% and 43.7% of the clonal hematopoiesis risk score's predictive value for leukemia and all-cause mortality, respectively. These findings reveal key biological determinants of CHIP progression and suggest that incorporating growth rate measurements could enhance risk stratification.

Indexed as

Clonal HematopoiesisAgedDioxygenasesDNA Methyltransferase 3AFemaleHumansJanus Kinase 2Longitudinal StudiesMiddle AgedMutationPostmenopauseDioxygenasesDNA Methyltransferase 3AJAK2 protein, humanJanus Kinase 2

Identifiers

PMID40499013
PMCPMC12952779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.